Kornimate/medical-research-clean huggingface dataset:
concurrent pemetrexed, cisplatin and radiation therapy in patients with stage iiia/b non small cell lung cancer

Conditions: Non-Small Cell Lung Cancer

Summary: measure the 1 year survival of non small cell lung cancer (nsclc) patients who are being treated with pemetrexed in combination with cisplatin and radiation.


Eligibility criteria:
inclusion criteria: some of the requirements to be in this study are: * patient must be at least 18 years old. * patient must have been diagnosed with non-small cell lung cancer. * patient must be able to visit the doctor's office once a week. * patient must have adequate blood, liver, lungs and kidney function within the requirements of this study. * female patients of child-bearing potential must test negative for pregnancy at the time of enrollment based on a serum pregnancy test. male and female patients must agree to use a reliable method of birth control during and for 3 months following the last dose of study drug. exclusion criteria: patients cannot participate in this study for any of the following reasons: * patient has previously had chemotherapy. * patient has previously had thoracic radiation therapy. * patient has received treatment within the last 30 days with a drug that has not received approval by health canada for any indication at the time of study entry. * female patient is pregnant or breast-feeding. * patient is unsuitable to participate in the study in the opinion of the investigator. * patient is unable or unwilling to take folic acid, vitamin b12 supplementation, or dexamethasone.
pain phenotype in patients with carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: the aim of this study was to determine the dominant pain phenotype in a group of patients with carpal tunnel syndrome by applying the international association for the study of pain (iasp) criteria.

voluntary participants between the ages of 18-65 who have been diagnosed with cts will be included in the study.the 7 steps in the clinical criteria/rating system determined by the international association for the study of pain (iasp) for nosiplastic pain and carpal tunnel syndrome will be applied to people with cts. thermal pain threshold, mechanical pain sensitivity and static/dynamic allodynia will be evaluated to determine pain hypersensitivity (step 5). specific questions will be asked to confirm the history of hypersensitivity in patients (step 6). finally, comorbidities, if any, will be determined (step 7). as a result, the pain phenotype of patients with cts will be determined (nociceptive, neuropathic or nosiplastic). shapiro-wilk test will be performed to determine the distribution of the data. one-way anova (continuous) or kruskal-wallis (categorical) will be used to examine whether the dependent variables differ between groups. for significant f-test, an additional investigation of differences between groups will be performed with gabriel's post hoc procedure.

Eligibility criteria:
inclusion criteria: * being diagnosed with cts * being between the ages of 18-65 * volunteering to participate in the study exclusion criteria: * having systemic inflammatory disease * having a disease that may cause polyneuropathy such as diabetes mellitus * having a pacemaker * having a disease affecting the central nervous system * having cervical radiculopathy * history of previous operation or local steroid injection due to cts * hypersensitivity to heat and cold
financial distress in patients with advanced cancer

Conditions: Cancer; Quality of Life

Summary: advanced cancer has an adverse effect in virtually all dimensions of patients' lives (physical, psychosocial, spiritual, familial, role function). one of the less frequently explored effects of cancer is its impact on personal finances and the contribution of financial-related distress to overall suffering and quality of life. financial issues have been recently found to be the second most frequent source of distress identified by cancer patients in a community cancer center context (22%). in the context of continuous increased health care costs, it is likely that the frequency of health care related financial problems will keep rising. the relative contribution of these adverse financial events in advanced cancer patients to overall patient distress is not well assessed and this is particularly true in france. the main objective of this work is to determine the association between financial distress and quality of life of patients with advanced cancer in a public general hospital and in a comprehensive cancer center. a secondary objective is to characterize the frequency and intensity of financial distress reported by french cancer patients and their impact on their quality of life.


Eligibility criteria:
inclusion criteria: * patients must be at least 18 years old and have a diagnosis of advanced cancer which is defined as one of the following: recurrent disease, received \>2 lines of chemotherapy, locally-advanced disease, metastatic disease, or refractory disease. * patients must have a cancer diagnosis of: breast, colon, lung or prostate. * patients must be able to understand, read, write, and speak french. exclusion criteria: * clinical evidence of cognitive impairment, as determined by the palliative care physician.

Keywords: cancer quality of life palliative care supportive care financial distress
the effect of calcium and vitamin d in patients with heart failure

Conditions: Heart Failure; Vitamin D Deficiency

Summary: previous studies have shown high proportions of vitamin d deficiency among elderly in denmark. vitamin d is important for muscular function. the investigators intend to examine if it is possible to improve cardiovascular function in patients with heart failure and vitamin d deficiency by supplementation with vitamin d.

heart failure (hf) is a major course of morbidity and mortality. the prevalence in the danish population is 1-2% and for age 50 -75 years: 2-3% (1) . it has been estimated that there are currently 6.5 million hf patients in europe and 5 million in the usa (2) . lack of vitamin d has been linked to heart disease including ischemic heart disease, heart failure, and hypertension.(3) vitamin d deficiency is prevalent in the elderly population. calcium absorption, bone mineralization and muscle function may be impaired. vitamin d receptors have also been demonstrated in skeletal as well as cardiac muscle(4) . vitamin d and parathyroid hormone (pth) are closely linked in the calcium metabolic system. in order to maintain serum calcium within range pth and vitamin d acts together in response to changes in serum-calcium levels. 25(oh)d concentration also being an important factor determining the levels of pth.(5) decreasing vitamin d leads to increasing levels of pth. hyperparathyroidism in patients with kidney-disease has in numerous studies been linked to cardiovascular disease, left ventricle hypertrophy, and valvular calcification .(6) aim: intervention with vitamin d and calcium will improve patients' vitamin d levels and suppress pth. thus we hope to find an improved cardiac function and quality of life in the intervention-group. comparison: cardiac function (and other effect parameters - such as self-evaluated health) in the intervention group vs. in the placebo-group

Eligibility criteria:
inclusion criteria: * over 18 years of age * vitamin d (serum 25-ohd): 50nmol/l or less * heart failure (ef 40% or less, nyha:2 or more) exclusion criteria: * calcium metabolic disturbances * granulomatous diseases * alcohol or drug abuse * intake of 400iu (or more) vitamin d/day * condition too poor to participate * pregnancy * af with hf 90 or above * mitral insufficiency, degree 3 or above * large cardiac aneurisms * significant aorta stenosis * significant aorta insufficiency * allergy to components
effect of rotating magnetic therapy on diabetic peripheral neuropathy

Conditions: Diabetic Peripheral Neuropathy

Summary: the aim of the study is to assess the eﬀect of rotating magnetic therapy on diabetic peripheral neuropathy using nerve conduction velocity examination.


Eligibility criteria:
inclusion criteria: - 1. volunteer to participate and sign informed consent prior to the study 2. patients with type 2 diabetes, who met who1999 diagnostic criteria, had diabetes distal symmetrical multiple neuropathy (1) clear history of diabetes; (2) neuropathy at or after diagnosis of diabetes;(3) clinical manifestations and signs are consistent with dpn;(4) have clinical symptoms (pain, numbness, paresthesia, etc.), 5 examination (ankle reflex, acupuncture pain sense, vibration sense, pressure sense, temperature sense) any 1 abnormal;if there were no clinical symptoms, 2 of the 5 examinations were abnormal.(5) exclude other causes of neuropathy). 3. hba1c\<7.5%, the hypoglycemic regimen was stable for 3 months 4. no acute complications, such as diabetic ketoacidosis, diabetic hyperosmolar syndrome, etc. exclusion criteria: * 1. patients with foreign metal bodies or pacemakers 2. patients with a history of surgery at magnetic therapy sites within one year 3. patients with obvious discomfort to magnetic therapy 4. patients with bleeding or bleeding tendency 5. patients with acute complications such as diabetic ketoacidosis 6. impaired liver and kidney function with alt 2.5 times higher than the upper limit of normal value;serum creatinine was 1.3 times higher than the upper limit of normal 7. history of drug abuse and alcohol dependence in the past 5 years 8. systemic hormone therapy was used in the last three months 9. patients with infection and stress within 4 weeks 10. patients who are pregnant, breast-feeding, or intending to become pregnant. 11. any other obvious conditions or co-existing diseases determined by the researcher: such as severe cardiopulmonary diseases, endocrine diseases, neurological diseases, tumors, other pancreatic diseases, patients with a history of mental illness, or severe wasting diseases
study to assess changes in immunoglobulins in patients with relapsing multiple sclerosis treated with anti-cd20 therapies

Conditions: Relapsing Multiple Sclerosis; Clinically Isolated Syndrome; Relapsing-remitting Multiple Sclerosis; Secondary Progressive Multiple Sclerosis

Summary: this was an observational retrospective cohort study using electronic medical records (emrs) to study immunoglobulin levels over time among patients with relapsing forms of multiple sclerosis (ms) newly initiating anti-cd20 monoclonal antibody treatment in clinical practice. the index date was defined as the date of anti-cd20 drug initiation during the study period. the baseline period was defined as 12 months prior to the index date.


Eligibility criteria:
inclusion criteria: * patients aged 18 years or older at index. * patients with rms, including clinically isolated syndrome (cis), relapsing-remitting multiple sclerosis (rrms), and secondary progressive multiple sclerosis (spms) at the time of initiating anti-cd20 treatment. * newly initiated anti-cd20 treatment after march 2017 (no history of anti-cd20 therapy at any time in medical record before this date) to the latest data cutoff (november 2022). * patients with at least one documented igg lab value pre- and post-anti-cd20 drug initiation. exclusion criteria: * patients with diagnosis of primary progressive multiple sclerosis (ppms) prior to anti-cd20 treatment. * participated in an anti-cd20 drug clinical trial during the study period.
comparison of the safety of flublok® versus licensed iiv in healthy, medically stable adults ≥ 50 years of age

Conditions: Influenza

Summary: the hypothesis for this trial is that the incidence of a pre-defined composite of common systemic hypersensitivity adverse events for flublok recipients is non-inferior to that reported for licensed iiv recipients. another hypothesis is that the safety and reactogenicity of flublok is clinically acceptable, i.e. consistent with the overall safety profiles previously observed with flublok and with the licensed comparator.

the advisory committee on immunization practices (acip) recommends that all people aged 6 months and older be immunized to prevent influenza. currently the only approved influenza vaccine across the entire age group is inactivated influenza vaccine (iiv). a biologics licensing application (bla) for flublok was approved by the fda for influenza immunization of adults 18-49 years of age. additional safety and, ultimately efficacy, data is needed to support use in adults ≥50 years of age, an important age group as adults ≥65 years of age are among those at increased risk of influenza complications.

Eligibility criteria:
inclusion criteria: 1. ambulatory adults aged 50 years and older 2. medically stable, as determined by medical history and targeted physical examination based on medical history, if appropriate 3. able to understand and comply with planned study procedures 4. provides written informed consent prior to initiation of any study procedure. exclusion criteria: 1. known contraindication to either study vaccine (see product package inserts) 2. receipt of any other influenza or other vaccine within 30 days prior to enrollment in this study. 3. receipt of any new medication within 30 days prior to enrollment in this study 4. plans to participate in any investigation involving an investigational product during this study. 5. pre-existence of atopic dermatitis or any other cutaneous disorder that could complicate the evaluation of potential primary endpoints. 6. any clinical or social circumstance that in the opinion of the investigator could interfere with compliance with study procedures or interfere with the interpretation of clinical data.

Keywords: influenza
does addition of oscillatory positive expiratory pressure (opep) device to a chest physiotherapy program provide further health benefits in children with bronchiectasis?

Conditions: Bronchiectasis

Summary: oscillatory positive expiratory pressure (opep) devices such as flutter®, aerobika® or shaker ® are commonly prescribed in the clinical practice for airway clearance in children with chronic lung diseases including bronchiectasis, cystic fibrosis, and primary ciliary dyskinesia. health insurance companies may cover these devices in some countries; but this is not a common practice around the world. therefore, many families have to purchase these devices themselves. unfortunately, these devices are rather expensive especially in the developing countries and consequently, families become financially burdened. aim of this study is to investigate whether the addition of opep devices to a comprehensive chest physiotherapy program provide additional benefits on pulmonary function and exercise capacity in children with bronchiectasis. results of this study may help better interpreting the cost-effectiveness of these devices.


Eligibility criteria:
inclusion criteria: * diagnosis of bronchiectasis exclusion criteria: * hospitalization history during past month * diagnosis of any other chronic childhood diseases such as cerebral palsy or neuromuscular diseases which may impede exercise tolerance

Keywords: bronchiectasis children oscillatory positive expiratory pressure device chest physiotherapy pulmonary function exercise capacity
patritumab with cetuximab and a platinum agent for squamous cell carcinoma (cancer) of the head and neck (scchn )

Conditions: Head and Neck Neoplasms

Summary: this study will test an investigational study drug called patritumab. it is a 'randomized study' which means participants have an equal chance of being assigned to receive the experimental medication (patritumab) or a substance that looks like the experimental product, but is not (placebo). patritumab may work when combined with other medications that are approved for the treatment of head and neck cancer. they are called cetuximab, cisplatin or carboplatin. all participants will receive the other medications approved for treatment of head and neck cancer, even if they do not receive the experimental product.

main objective of the trial: the main objective of the trial is to evaluate progression-free survival (pfs) in the heregulin (hrg) high expression population from subjects treated with patritumab + cetuximab + platinum-based therapy compared to placebo + cetuximab + platinum-based therapy.

Eligibility criteria:
inclusion criteria: * has histologically confirmed recurrent disease or metastatic scchn tumor and/or from its lymph nodal metastases originating from the oral cavity, oropharynx, hypopharynx, and larynx * has or be willing to provide tumor tissue for testing * has measurable disease per response evaluation criteria in solid tumor (recist) version 1.1 * has eastern cooperative oncology group (ecog) performance status 0 or 1 * has adequate hematological function per protocol * has adequate renal function per protocol * has adequate hepatic function per protocol * agrees to use effective contraception while on the study and for 6-months after the end of the study * provides written informed consent(s) exclusion criteria: * has left ventricular ejection fraction (lvef) \<50% * had prior epidermal growth factor receptor (egfr) targeted regimen * had prior anti-human epidermal growth factor receptor 3 (anti-her3) therapy * had prior chemotherapy for recurrent/metastatic disease * had anti-cancer therapy between biopsy and submission of sample * has history of other malignancies, except adequately treated non-melanoma skin cancer, curatively treated in-situ disease, or other solid tumors curatively treated with no evidence of disease for ≥ 2 years * has known history of brain metastases or active brain metastases * has uncontrolled hypertension * has clinically significant electrocardiograph (ecg) findings * had myocardial infarction within 1 year before enrollment, symptomatic congestive heart failure, unstable angina, or arrhythmia requiring medication * had platinum-containing drug therapy with radiotherapy less than 6 months before study drug treatment * had therapeutic or palliative radiation therapy or major surgery within 4 weeks before study drug treatment

Keywords: squamous cell cancer of the head and neck squamous cell carcinoma head and neck cancer neoplasms by site
atorvastatin after aneurysmal subarachnoid hemorrhage

Conditions: SAH

Summary: the 3-hydroxy-3-methylglutaryl coenzyme a (hmg-coa) reductase inhibitors, known as statins, have recently been demonstrated to improve endothelial function. additionally, numerous studies have shown statins as having antiinflammatory and cell-signaling effects together with a selective up-regulation of the enos activity. these findings are of potential benefit for the prevention of cerebral vasospasm after a aneurysmal subarachnoid hemorrhage. indeed, one of the possible mechanisms for this vasospasm is the enos depletion or even increase of enos expression after the hemorrhage. the purpose of this study is to observe the immediate effect of statins after aneurysmal subarachnoid hemorrhage (asah) in cerebral vasospasm and outcome at one year.

up to now, the preventive and curative treatment of vasospasm secondary to subarachnoid aneurismal hemorrhage has been based on three major approaches: increasing arterial pressure and cerebral blood flow with the use of triple h therapy, increasing the ischemic threshold of neurons with nimodipine and reopening proximal arteries with angioplasty and/or intra-arterial administration of nimodipine, verapamil, milrinone or papaverine. recently, several teams have observed the efficacy of diverse statins in the prevention of vasospasm by improving the imbalance between the nitric oxide and the endothelin pathways, a major actor in the physiopathology of vasospasm. indeed, this family of molecules improve the bioavailability of endogenous nitric oxide and upregulate the endothelial no synthase. in humans, statin administered within the first 72 hours showed to significantly reduce the incidence of vasospasm up to 50% an therefore, induce a lower morbidity and mortality of this severely ill population. the aim of this study is to demonstrate that atorvastatin reduces the incidence of cerebral vasospasm-related morbidity and mortality within 1 year post aneurysmal subarachnoid hemorrhage (asah) treated by either clipping or endovascular coiling.

Eligibility criteria:
inclusion criteria: * sah patient \> 16 years-old admitted to the pitie- salpetriere teaching hospital * securing procedure within 96 hours of bleeding exclusion criteria: * securing procedure \> 96 hours of bleeding * rebleeding of original aneurysm
effects of macular buckle versus vitrectomy on macular schisis and macular detachment in highly myopic eyes

Conditions: Retinoschisis; Macular Detachment; High Myopia

Summary: macular schisis associated with macular detachment is a one of the complications of high myopia. there is controversy in the primary treatment for this situation. this study will compare the effects of macular buckling + gas injection versus vitrectomy + internal limiting membrane peeling + gas tamponade in a cohort of highly myopic eyes with macular retinal detachment associated with macular schisis.

a randomized, open label, single center study comparing the efficacy of macular muckle + gas injection versus internal limiting membrane peeling + gas tamponade on macular schisis associated with macular detachment in eyes with high myopia.

Eligibility criteria:
inclusion criteria: * axial length ≥ 26.5 mm or refractive error (spherical equivalent) ≥ 8.0 diopter * macular schisis * macular retinal detachment * evidence of posterior staphyloma on clinical examination exclusion criteria: * severe macular scar * macular detachment which extended to the peripheral retina (i.e., extension beyond the major vascular arcades in more than one quadrant) * prominent vitreomacular traction * a history of vitrectomy or macular buckle * intraocular active hemorrhage or inflammation * any media opacity which precluded imaging or clinical evaluation of the macula